C07K5/11

PEPTIDES OF USE IN THE PREVENTIVE AND CURATIVE TREATMENT OF ALOPECIA

The object of the present invention relates to a novel family of peptide conjugates of formula (I):


A-X.sub.1—X.sub.2-Pro-Ala-X—B   (I) wherein: A represents a hydrogen atom, a C.sub.6 to C.sub.20 acyl group or a cholesterol residue; X.sub.1 represents a covalent bond, an alanine or a proline; X.sub.2 represents an arginine, a lysine, or an alanine; X represents a lysine, an alanine, or a phenylalanine; and B represents a hydroxyl or an amine; or one of its preferentially pharmaceutically, dermatologically or cosmetically acceptable salts, as well as their synthesis processes and their uses for reducing hair loss and stimulating hair growth.

Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient

Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH.SUB.2
11034724 · 2021-06-15 · ·

Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH.sub.2.

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

AROMATIC-CATIONIC PEPTIDES AND USES OF SAME
20210130402 · 2021-05-06 · ·

The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.

N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE ANTIBODIES THERETO
20210154315 · 2021-05-27 ·

The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION

The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, R.sup.5a and R.sup.5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.

##STR00001##

PEPTIDE-COMPRISING ELECTRODE

The present application relates to an electrode suitable for use in electrochemical sensing of a target species. The electrode comprises a peptide monolayer of defined length and to one end of which are attached both a redox active species and a receptor that is capable of binding to the target species. Also provided is an electrochemical method of sensing a target species, which involves the use of the electrode.